PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

被引：218

作者：

Carpinelli, Patrizia ^{[1
]}

Ceruti, Roberta ^{[1
]}

Giorgini, Maria Laura ^{[1
]}

Cappella, Paolo ^{[1
]}

Gianellini, Laura ^{[1
]}

Croci, Valter ^{[1
]}

Degrassi, Anna ^{[1
]}

Texido, Gernma ^{[1
]}

Rocchetti, Maurizio ^{[1
]}

Vianello, Paola ^{[1
]}

Rusconi, Luisa ^{[1
]}

Storici, Paola ^{[1
]}

Zugnoni, Paola ^{[1
]}

Arrigoni, Claudio ^{[1
]}

Soncini, Chiara ^{[1
]}

Alli, Cristina ^{[1
]}

Patton, Veronica ^{[1
]}

Marsiglio, Aurelio ^{[1
]}

Ballinari, Dario ^{[1
]}

Pesenti, Enrico ^{[1
]}

Fancelli, Daniele ^{[1
]}

Moll, Jurgen ^{[1
]}

机构：

[1] Nerviano Med Sci SRI Oncol, I-20014 Milan, Italy

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

10.1158/1535-7163.MCT-07-0444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status-dependent endoreduplication is observed upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser(10) is inhibited. The compound has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile. In vivo target modulation is observed as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clinical phase. Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clinical doses and schedules. We conclude that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.

引用

页码：3158 / 3168

页数：11

共 49 条

[11] Dagher R, 2002, CLIN CANCER RES, V8, P3034
[12] Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all?
de Jonge, M. J. A.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) : 1351 - 1356
[13] Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials
Degrassi, Anna
Russo, Micaela
Scanziani, Eugenio
Giusti, Anna
Ceruti, Roberta
Texido, Gernma
Pesenti, Enrico
[J]. PROSTATE, 2007, 67 (04) : 396 - 404
[14] Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores
Ditchfield, C
Johnson, VL
Tighe, A
Ellston, R
Haworth, C
Johnson, T
Mortlock, A
Keen, N
Taylor, SS
[J]. JOURNAL OF CELL BIOLOGY, 2003, 161 (02) : 267 - 280
[15] Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene:: a meta-analysis of multiple cancer types
Ewart-Toland, A
Dai, Q
Gao, YT
Nagase, H
Dunlop, MG
Farrington, SM
Barnetson, RA
Anton-Culver, H
Peel, D
Ziogas, A
Lin, DX
Miao, XP
Sun, T
Ostrander, EA
Stanford, JL
Langlois, M
Chan, JM
Yuan, JW
Harris, CC
Bowman, ED
Clayman, GL
Lippman, SM
Lee, JJ
Zheng, W
Balmain, A
[J]. CARCINOGENESIS, 2005, 26 (08) : 1368 - 1373
[16] Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition
Fancelli, D
Berta, D
Bindi, S
Cameron, A
Cappella, P
Carpinelli, P
Catana, C
Forte, B
Giordano, P
Giorgini, ML
Mantegani, S
Marsiglio, A
Meroni, M
Moll, J
Pittalà, V
Roletto, F
Severino, D
Soncini, C
Storici, P
Tonani, R
Varasi, M
Vulpetti, A
Vianello, P
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) : 3080 - 3084
[17] 1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles:: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile
Fancelli, Daniele
Moll, Jurgen
Varasi, Mario
Bravo, Rodrigo
Artico, Roberta
Berta, Daniela
Bindi, Simona
Cameron, Alexander
Candiani, Ilaria
Cappella, Paolo
Carpinelli, Patrizia
Croci, Walter
Forte, Barbara
Giorgini, Maria Laura
Klapwijk, Jan
Marsiglio, Aurelio
Pesenti, Enrico
Rocchetti, Maurizio
Roletto, Fulvia
Severino, Dino
Soncini, Chiara
Storici, Paola
Tonani, Roberto
Zugnoni, Paola
Vianello, Paola
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) : 7247 - 7251
[18] A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
Fiedler, W
Serve, H
Döhner, H
Schwittay, M
Ottmann, OG
O'Farrell, AM
Bello, CL
Allred, R
Manning, WC
Cherrington, JM
Louie, SG
Hong, W
Brega, NM
Massimini, G
Scigalla, P
Berdel, WE
Hossfeld, DK
[J]. BLOOD, 2005, 105 (03) : 986 - 993
[19] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Giles, Francis J.
Cortes, Jorge
Jones, Dan
Bergstrom, Donald
Kantarjian, Hagop
Freedman, Steven J.
[J]. BLOOD, 2007, 109 (02) : 500 - 502
[20] The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function
Gizatullin, Farid
Yao, Yao
Kung, Victor
Harding, Matthew W.
Loda, Massimo
Shapiro, Geoffrey I.
[J]. CANCER RESEARCH, 2006, 66 (15) : 7668 - 7677

← 1 2 3 4 5 →